NCHR Testimony at the FDA Advisory Committee Meeting on Lorcaserin

September 16, 2010. The studies are an important reminder that behavior modification is a safe and effective alternative to diet pills. Lorcaserin does not appear to be effective for most patients, and especially not for most African-American or Latino patients. More extensive research is needed on the risks.

Read More »

Testimony on Acurox

April 22, 2010. Although Acura Pharmaceuticals should be applauded for trying to reduce the misuse and abuse of oxycondone, the key question is: can Acurox easily be abused?

Read More »